24 reports

  • 4.1.1 ETIOLOGY
  • 5.7.1 EPIDEMIOLOGICAL FORECAST INSIGHT

Oral Contraceptive and Cancer Risks.

  • Breast Cancer
  • Company
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • 2.3 Etiology
  • 9.3 Bibliography

Oral contraceptives and breast cancer risk in Taiwan, a country of low incidence of breast cancer and low use of oral contraceptives.

  • Breast Cancer
  • Cancer
  • AstraZeneca PLC
  • Novartis AG
  • Roche Group
  • HUGE MARKET POTENTIAL FOR BREAST CANCER MABS OWING TO PRODUCT APPROVALS

For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer.

  • Breast Cancer
  • Amgen Inc.
  • Biocon Limited
  • Mylan Inc.
  • Roche Group
  • 3.1 ETIOLOGY AND PATHOPHYSIOLOGY

Combination hormone products, such as the estrogen + progestin contraceptive pill, have also been associated with an increased risk of breast cancer (NCI, 2016).

  • Breast Cancer
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • 2.1.2 Causes of Breast Cancer

The Aptima HIV-## Quant assay is not approved for HIV-## diagnosis in the United States.

  • Breast Cancer
  • World
  • Business Expansion & Exit
  • Demand
  • Hologic, Inc.
  • Breast Cancer Therapeutics Market, Taiwan, Market Size ($m), 2015-2022
  • Breast Cancer Therapeutics, South Korea, Age-Specific Incidence (%), 2012

Oral contraceptives and breast cancer risk in Taiwan, a country of low Journal of the National Cancer incidence of breast cancer and low use of oral contraceptives.

  • Breast Cancer
  • Market Size
  • AstraZeneca PLC
  • Genentech, Inc.
  • Novartis AG

For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer.

  • Breast Cancer
  • World
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • 2.7.1 Epidemiological Forecast Insight

Chronic Diseases and Translational Medicine; ##(##): ##-##.

  • Breast Cancer
  • China
  • Japan
  • United States
  • Forecast

These include oral contraceptive use, multiple pregnancies and prolonged lactation.

  • Breast Cancer
  • Market Size
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Merck & Co., Inc.
  • REFERRAL IS DICTATED BY STAGE AT DIAGNOSIS AND ELECTED TREATMENT APPROACH

Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, et al. (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.

  • Breast Cancer
  • European Union
  • Japan
  • United States
  • TESARO, Inc.
  • 2.3 ETIOLOGY

Combination hormone products, such as the estrogen and progestin contraceptive pill, have also been associated with an increased risk of breast cancer (NCI, 2013).

  • Breast Cancer
  • Market Size
  • Genentech, Inc.
  • Novartis AG
  • Pfizer Inc.
  • 14. Market Growth Drivers

The use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing the disease.

  • Breast Cancer
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche Inc.

Quartette is an oral contraceptive indicated for the prevention of pregnancy.

  • Breast Cancer
  • Hormone
  • United States
  • World
  • Product Initiative
  • NOV 14, 2017: FASLODEX (FULVESTRANT) RECEIVES EU APPROVAL FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB
  • DEC 06, 2017: H3 BIOMEDICINE PRESENTS PRECLINICAL DATA ON NOVEL ERA ANTAGONIST AT SAN ANTONIO BREAST CANCER SYMPOSIUM

We believe that Estelle has the potential to become a true ' next - generation' contraceptive option, including in North America, a market worth ##% of the USD ##bn worldwide contraceptive market.

  • Breast Cancer
  • Hormone
  • Hospital
  • Product Initiative
  • Mithra
  • (ER+) breast cancer. The trial was registered with the U.S. National Institutes of Health.

Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises ##, ## and ## molecules, respectively.

  • Breast Cancer
  • Hormone
  • United States
  • World
  • Product Initiative
  • GLOBAL INCIDENCE OF BREAST CANCER, 2012-2025
  • MARKET DYNAMICS (2/10)

This can majorly be attributed to changing lifestyles, increasing use of oral contraceptives, and the growing number of women undergoing cosmetic surgeries such as breast enhancement.

  • Breast Cancer
  • North America
  • United States
  • Forecast
  • Cianna Medical, Inc.

Quartette is an oral contraceptive indicated for the prevention of pregnancy.

  • Breast Cancer
  • Hormone
  • United States
  • World
  • Product Initiative
  • 10.2 PARENTERAL

Use of birth control contraceptives and hormonal therapy after menopause increase the risk for developing breast cancer as they contain synthetic sex hormones.

  • Breast Cancer
  • United States
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc

Patients were randomized into one of four arms (mirogabalin ## mg once-daily, mirogabalin ## mg twice-daily, mirogabalin ## mg twice-daily or placebo) at the ratio of ##:##:##:##, respectively.

  • Breast Cancer
  • Pharmaceutical
  • Japan
  • United States
  • Daiichi Sankyo Company
  • 4.4.2 Genetics
  • 4.3 DIAGNOSIS

Higher estrogen levels can be associated with the use of hormone replacement therapy and oral contraceptives (Institute of Medicine Committee, 1991).

  • Breast Cancer
  • Cancer
  • Monoclonal Antibody
  • Pathology
  • Therapy

ASTRAZENECA REGISTERED A PHASE I SINGLE-BLIND, PLACEBO-CONTROLLED, ##-PERIOD, FIXED SEQUENCE STUDY TO EVALUATE THE SAFETY, EFFICACY AND TOLERABILITY OF COADMINISTRATION OF FOSTAMATINIB ## MG TWICE DAILY ON THE PHARMACOKINETICS OF AN ORAL CONTRACEPTIVE IN HEALTHY FEMALE SUBJECTS.

  • Breast Cancer
  • Hospital
  • Ovarian Cancer
  • Therapy
  • Merck & Co., Inc.

GLAXOSMITHKLINE REGISTERED A PHASE I OPEN-LABEL, NON-RANDOMIZED, SEQUENTIAL, TWO-PERIOD, REPEAT-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF TRAMETINIB ON COMBINED ORAL CONTRACEPTIVE (NORETHINDRONE PLUS ETHINYL ESTRADIOL) IN FEMALE SUBJECTS WITH SOLID TUMORS.

  • Breast Cancer
  • Cell Therapy
  • United States
  • Company
  • Product Initiative
  • Clinical and Commercial Landscape

Other major lifestyle factors are generally related to estrogen levels and include hormone replacement therapy and the use of oral contraceptives, which both raise the level of circulating estrogen.

  • Breast Cancer
  • Cancer
  • Pathology
  • Therapy
  • Deals & Alliance
  • BREAST CANCER: GLOBAL INCIDENCE AND MORTALITY AMONG WOMEN

This can majorly be attributed to changing lifestyles, increasing use of oral contraceptives, and growing number of women undergoing cosmetic surgeries like breast enhancement.

  • Breast Cancer
  • North America
  • United States
  • World
  • Market Size